BofA Securities analyst Tazeen Ahmad maintains $PTC Therapeutics (PTCT.US)$ with a sell rating, and adjusts the target price from $32 to $30.
According to TipRanks data, the analyst has a success rate of 51.9% and a total average return of 3.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
PTC Therapeutics recently disclosed Q2 results, indicating sales of Translarna at $70.4M and Emflaza also at $70.4M. There is ongoing uncertainty regarding Translarna's continued availability in EU markets following several unfavorable opinions from the Committee for Medicinal Products for Human Use (CHMP). A decisive CHMP opinion is anticipated by mid-October, which could lead to Translarna's withdrawal from EU markets within 67 days if the opinion is adverse. The company's pipeline programs are believed to require further risk reduction.
Estimates on PTC Therapeutics are modestly surpassing the consensus regarding Translarna net product revenues while aligning with expectations on Emflaza net product revenue, according to an analyst overview. The focus for the upcoming discussion will include details about the CHMP re-examination procedures and insights on the submission of further information demanded by the FDA pertaining to the NDA re-submission.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Tazeen Ahmad維持$PTC Therapeutics (PTCT.US)$賣出評級，並將目標價從32美元下調至30美元。
根據TipRanks數據顯示，該分析師近一年總勝率為51.9%，總平均回報率為3.9%。
此外，綜合報道，$PTC Therapeutics (PTCT.US)$近期主要分析師觀點如下：
PTC Therapeutics最近公佈了第二季度業績，顯示Translarna的銷售額爲7,040萬美元，Emflaza的銷售額也爲7.04萬美元。在人用藥品委員會（CHMP）提出了幾項不利意見之後，Translarna在歐盟市場的持續供應仍然存在不確定性。預計CHMP將在10月中旬發表決定性的意見，如果意見不佳，這可能導致Translarna在67天內退出歐盟市場。據信，該公司的管道計劃需要進一步降低風險。
分析師的概述顯示，對PTC Therapeutics的估計略高於對Translarna淨產品收入的共識，同時與對Emflaza淨產品收入的預期一致。即將舉行的討論的重點將包括有關CHMP複審程序的詳細信息以及對FDA要求提交與重新提交保密協議有關的進一步信息的見解。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
